Copyright

Image from here [This post is authored by Bharathwaj Ramakrishnan. Bharathwaj is a 3rd year LLB Student at RGSOIPL, IIT Kharagpur, and loves books and IP. His previous posts can be accessed here.] In the first part of the post, we dealt with the relevant background, wherein I stated that it is useful to see any […]

Image from here [This post is authored by Bharathwaj Ramakrishnan. Bharathwaj is a 3rd year LLB Student at RGSOIPL, IIT Kharagpur, and loves books and IP. His previous posts can be accessed here.] As perhaps all readers are aware by now, the GenAI Copyright litigations have made their presence known in India. As discussed earlier, ANI

Image: Shutterstock.com/Deemerwha studio The need to raise awareness of copyright compliance and AI tools is more important than ever to avoid risks like copyright infringement, according to a new study published by Copyright Clearance Center. The Copyrighted Content Usage Trends Report, published in conjunction with Outsell, analyses insights from executive-level respondents – revealing that while

2025 Copyrighted Content Usage Trends Report Confirms That Widespread Adoption of AI and Online Collaboration Platforms Has Increased Potential Enterprise Risk Related to Copyright Compliance January 28, 2025 – Danvers, Mass. –  CCC, a leader in advancing copyright, accelerating knowledge, and powering innovation, today announced key findings on attitudes about copyright, the adoption of AI

Image by macrovector. See here. [This post has been authored by SpicyIP intern Aditi Agrawal. Aditi is a final-year B.A., LL.B (IPR Hons.) student at The ICFAI University, Dehradun. Her previous posts can be accessed here.] On 26th December 2024, the Delhi Government issued a gazette notification (F. No. 11/24/2024/HP-II/4236-4244), designating Delhi Police as the

Here is our recap of last week’s top IP developments including summary of the post on the analysis of Delhi HC’s judgment in Master Arnesh Shaw, a letter by MP Haris Beeran to the Government urging to invoke Section 100, Patents Act for rare disease medicine, and the statutory duty under Section 151 of Patents